Market Summary
USD1.74+0.03
Delayedas of 03 Oct 2023, 09:56 am1.75%
DNA Stock Price
DNA RSI Chart
DNA Valuation
DNA Price/Sales (Trailing)
DNA Profitability
DNA Fundamentals
DNA Revenue
DNA Earnings
Price Action
52 Week Range
1.123.52
(Low)(High)
Last 7 days
-1.2%
Last 30 days
-24%
Last 90 days
-3.9%
Trailing 12 Months
-45.2%
DNA Financial Health
DNA Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for DNA
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-28 | Kelly Jason R | sold | -174,900 | 1.749 | -100,000 | see remarks |
2023-09-28 | Canton Barry | sold | -65,887 | 1.75 | -37,650 | - |
2023-09-28 | Shetty Reshma P. | sold | -65,887 | 1.75 | -37,650 | see remarks |
2023-09-27 | Shetty Reshma P. | sold | -68,899 | 1.83 | -37,650 | see remarks |
2023-09-27 | Canton Barry | sold | -68,899 | 1.83 | -37,650 | - |
2023-09-27 | Kelly Jason R | sold | -182,500 | 1.825 | -100,000 | see remarks |
2023-09-21 | Kelly Jason R | sold | -176,600 | 1.766 | -100,000 | see remarks |
2023-09-21 | Canton Barry | sold | -66,452 | 1.765 | -37,650 | - |
2023-09-21 | Shetty Reshma P. | sold | -66,452 | 1.765 | -37,650 | see remarks |
2023-09-20 | Shetty Reshma P. | sold | -69,238 | 1.839 | -37,650 | see remarks |
Which funds bought or sold DNA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | new | - | 21,604 | 21,604 | -% |
2023-09-20 | BARCLAYS PLC | reduced | -55.97 | -401,000 | 644,000 | -% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | new | - | 1,860 | 1,860 | -% |
2023-08-23 | WOLVERINE TRADING, LLC | added | 151 | 56,767 | 77,767 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 26.51 | 1,087,050 | 2,500,150 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 4.41 | 175,770 | 556,647 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -15.52 | 54.00 | 286 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | 486,000 | 1,703,000 | 0.02% |
2023-08-17 | Coastal Bridge Advisors, LLC | new | - | 669,600 | 669,600 | 0.16% |
2023-08-17 | Coastal Bridge Advisors, LLC | unchanged | - | 888 | 2,832 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Ginkgo Bioworks Holdings
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | che austin | 6.3% | 99,857,282 | SC 13G/A | |
| Feb 14, 2023 | knight thomas f. jr. | 5.0% | 74,936,116 | SC 13G/A | |
| Feb 14, 2023 | anchorage capital group, l.l.c. | 4.83% | 69,904,593 | SC 13G/A | |
| Feb 14, 2023 | viking global investors lp | 9.36% | 143,085,126 | SC 13G/A | |
| Feb 13, 2023 | general atlantic, l.p. | 2.4% | 32,319,896 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 7.49% | 101,521,280 | SC 13G | |
| Jan 25, 2023 | shetty reshma p. | 12.0% | 195,788,523 | SC 13D/A | |
| Jan 25, 2023 | kelly jason r | 6.2% | 97,017,435 | SC 13D/A | |
| Jan 23, 2023 | baillie gifford & co | 18.03% | 244,176,643 | SC 13G/A | |
| Jul 01, 2022 | viking global investors lp | 9.7% | 115,084,128 | SC 13G |
Recent SEC filings of Ginkgo Bioworks Holdings
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Oct 02, 2023 | 144 | Notice of Insider Sale Intent | |
| Oct 02, 2023 | 144 | Notice of Insider Sale Intent | |
| Oct 02, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 29, 2023 | 4 | Insider Trading | |
| Sep 29, 2023 | 4 | Insider Trading | |
| Sep 29, 2023 | 4 | Insider Trading | |
| Sep 29, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 28, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 28, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 28, 2023 | 144 | Notice of Insider Sale Intent |
Ginkgo Bioworks Holdings News
Returns for DNA
Cumulative Returns on DNA
Risks for DNA
What is the probability of a big loss on DNA?
75.2%
Probability that Ginkgo Bioworks Holdings stock will be more than 20% underwater in next one year
75.2%
Probability that Ginkgo Bioworks Holdings stock will be more than 30% underwater in next one year.
72.1%
Probability that Ginkgo Bioworks Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does DNA drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Ginkgo Bioworks Holdings was unfortunately bought at previous high price.
Drawdowns
Financials for Ginkgo Bioworks Holdings
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
| Revenue | -16.4% | 325,953,000 | 390,003,000 | 477,706,000 | 527,915,000 | 539,127,000 | 438,145,000 | 313,837,000 | 197,401,000 | 133,093,000 | 119,276,000 | 76,657,000 | 53,208,000 | 54,184,000 |
| Operating Expenses | -24.6% | 1,613,378,000 | 2,141,056,000 | 2,686,658,000 | 4,188,821,000 | 3,573,684,000 | 2,884,868,000 | 2,142,304,000 | 397,021,000 | 340,454,000 | 315,830,667 | 213,684,000 | 190,860,000 | 125,782,000 |
| S&GA Expenses | -50.1% | 446,925,333 | 895,040,000 | 1,429,799,000 | - | 1,665,349,333 | - | 862,952,000 | 62,521,333 | - | 37,077,333 | 19,762,000 | 39,504,000 | 29,483,000 |
| R&D Expenses | -16.3% | 747,656,000 | 893,433,000 | 1,052,643,000 | 1,858,240,000 | 1,651,681,000 | 1,413,653,000 | 1,149,662,000 | 225,828,000 | 208,877,000 | 209,128,000 | 159,767,000 | 144,280,000 | 96,299,000 |
| EBITDA | 100.0% | - | -1,665,891,000 | -2,078,741,000 | -3,490,597,000 | -3,033,922,000 | -2,220,765,145 | -1,818,701,000 | -135,043,545 | -145,464,211 | -62,942,200 | -98,777,000 | -58,161,333 | -157,317,000 |
| EBITDA Margin | 100.0% | - | -4.27 | -4.35 | -6.61 | -5.63 | -5.07 | -5.80 | -0.68 | -1.09 | -0.82 | -1.29 | -1.09 | -2.90 |
| Interest Expenses | 77.3% | 27,723,000 | 15,638,000 | 106,000 | 11,761,000 | 5,413,000 | 2,671,000 | 2,373,000 | -1,792,000 | 7,029,000 | 10,009,333 | 2,385,000 | 33,172,000 | 2,421,000 |
| Earnings Before Taxes | 28.7% | -1,236,142,000 | -1,733,509,000 | -2,121,399,000 | -3,538,153,000 | -2,971,682,000 | -2,355,962,000 | -1,838,122,000 | -278,835,000 | -202,343,000 | -196,597,333 | -124,834,000 | -104,480,000 | -119,835,000 |
| EBT Margin | 100.0% | - | -4.44 | -4.44 | -6.70 | -5.51 | -5.50 | -5.86 | -1.27 | -1.30 | -1.16 | -1.63 | -1.96 | -2.21 |
| Net Income | 28.8% | -1,223,883,000 | -1,719,393,000 | -2,104,929,000 | -3,529,041,000 | -2,961,867,000 | -2,346,983,000 | -1,830,047,000 | -229,396,000 | -153,570,000 | -128,359,000 | -80,258,000 | -107,004,000 | -119,327,000 |
| Net Income Margin | 100.0% | - | -4.41 | -4.41 | -6.68 | -5.49 | -5.48 | -5.83 | -1.03 | -0.95 | -0.64 | -1.05 | -2.01 | -2.20 |
| Free Cashflow | 100.0% | - | -391,017,000 | -304,469,000 | -344,778,000 | -313,676,000 | -311,411,562 | -310,339,000 | -159,097,000 | -197,898,666 | -58,761,876 | -57,821,000 | -153,198,666 | -66,882,000 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
| Assets | -5.2% | 2,292 | 2,417 | 2,539 | 1,871 | 1,994 | 2,058 | 2,071 | 2,151 | 1,726 | 1,728 | 675 | 697 |
| Current Assets | -7.8% | 1,223 | 1,327 | 1,450 | 1,462 | 1,599 | 1,706 | 1,723 | 1,811 | 1.00 | 3.00 | 427 | 512 |
| Cash Equivalents | -8.3% | 1,106 | 1,206 | 1,316 | 1,303 | 1,377 | 1,493 | 1,550 | 1,739 | 236 | 308 | 381 | 495 |
| Inventory | -84.4% | 0.00 | 3.00 | 4.00 | 6.00 | 8.00 | 9.00 | 3.00 | 3.00 | - | - | 3.00 | - |
| Net PPE | -6.3% | 294 | 314 | 315 | 188 | 176 | 149 | 146 | 143 | - | - | 121 | 63.00 |
| Goodwill | 0.2% | 59.00 | 59.00 | 60.00 | 29.00 | 31.00 | 21.00 | 21.00 | 17.00 | - | - | 2.00 | 2.00 |
| Liabilities | -2.6% | 788 | 810 | 803 | 431 | 427 | 444 | 504 | 533 | 255 | 150 | 205 | 195 |
| Current Liabilities | -14.8% | 163 | 192 | 173 | 125 | 135 | 159 | 135 | 90.00 | 5.00 | 1.00 | 73.00 | 40.00 |
| Shareholder's Equity | -6.5% | 1,504 | 1,608 | 1,736 | 1,435 | 1,572 | 1,619 | 1,567 | 1,618 | 356 | 396 | 470 | 502 |
| Retained Earnings | -3.8% | -4,775 | -4,602 | -4,397 | -4,226 | -3,557 | -2,888 | -2,297 | -697 | -101 | 5.00 | -467 | -341 |
| Additional Paid-In Capital | 1.1% | 6,281 | 6,212 | 6,136 | 5,669 | 5,098 | 4,471 | 3,805 | 2,250 | 106 | - | 929 | - |
| Shares Outstanding | - | 1,933 | - | - | 1,631 | 1,621 | 1,607 | 1,611 | 1,324 | 1,293 | 1,290 | 1,289 | 1,256 |
| Minority Interest | - | - | - | - | 5.00 | 32.00 | 33.00 | 62.00 | 66.00 | - | - | 9.00 | 9.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
| Cashflow From Operations | 8.0% | -297 | -322 | -252 | -313 | -290 | -225 | -253 | -88.28 | -110 | -96.26 | - | -101 | -44.66 |
| Share Based Compensation | -40.3% | 806 | 1,351 | 1,931 | 3,414 | 2,851 | 2,259 | 1,606 | 15.00 | 20.00 | 0.00 | 0.00 | 0.00 | 1.00 |
| Cashflow From Investing | 6.8% | -47.38 | -50.82 | -67.39 | -92.91 | -76.93 | -86.20 | -73.26 | -106 | -101 | -103 | -67.12 | -51.05 | -74.60 |
| Cashflow From Financing | -0.6% | 95.00 | 96.00 | 95.00 | -13.64 | 1,535 | 1,533 | 1,534 | 1,545 | -3.66 | -1.24 | 90.00 | 121 | 410 |
| Buy Backs | - | - | - | - | - | - | - | 25.00 | 100 | - | - | - | - | 0.00 |
DNA Income Statement
2023-06-30Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | [1] | |||||
| Biosecurity revenue: | |||||||||
| Total Revenue | $ 80,568 | $ 144,618 | $ 161,270 | $ 313,023 | |||||
| Costs and operating expenses: | |||||||||
| Research and development | 144,282 | 290,059 | 306,921 | 613,635 | |||||
| General and administrative | 102,341 | 438,427 | 213,774 | 873,195 | |||||
| Total operating expenses | 264,719 | 792,397 | 561,166 | 1,636,173 | |||||
| Loss from operations | (184,151) | (647,779) | (399,896) | (1,323,150) | |||||
| Other income (expense): | |||||||||
| Interest income, net | 14,349 | 2,264 | 28,894 | 2,441 | |||||
| Loss on equity method investments | (67) | (10,166) | (1,516) | (31,053) | |||||
| Loss on investments | (2,121) | (38,673) | (8,491) | (38,223) | |||||
| Change in fair value of warrant liabilities | (4,482) | 23,509 | (3,278) | 108,544 | |||||
| Gain on deconsolidation of subsidiary | 0 | 0 | 0 | 15,900 | |||||
| Other income, net | 3,224 | 230 | 6,152 | 2,149 | |||||
| Total other income (expense), net | 10,903 | (22,836) | 21,761 | 59,758 | |||||
| Loss before income taxes | (173,248) | (670,615) | (378,135) | (1,263,392) | |||||
| Income tax expense (benefit) | 67 | (45) | 149 | (229) | |||||
| Net loss | (173,315) | (670,570) | (378,284) | (1,263,163) | |||||
| Loss attributable to non-controlling interest | 0 | (1,745) | 0 | (3,833) | |||||
| Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders | $ (173,315) | $ (668,825) | $ (378,284) | $ (1,259,330) | |||||
| Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders: | |||||||||
| Basic | $ (0.09) | $ (0.41) | $ (0.2) | $ (0.78) | |||||
| Diluted | $ (0.09) | $ (0.41) | $ (0.2) | $ (0.78) | |||||
| Weighted average common shares outstanding | |||||||||
| Basic | 1,933,437 | 1,620,704 | 1,924,251 | 1,614,138 | |||||
| Diluted | 1,933,437 | 1,620,704 | 1,924,251 | 1,614,138 | |||||
| Comprehensive loss: | |||||||||
| Net loss | $ (173,315) | $ (670,570) | $ (378,284) | $ (1,263,163) | |||||
| Other comprehensive income (loss): | |||||||||
| Foreign currency translation adjustment | 314 | (3,141) | 1,332 | (3,781) | |||||
| Total other comprehensive income (loss) | 314 | (3,141) | 1,332 | (3,781) | |||||
| Comprehensive loss | (173,001) | (673,711) | (376,952) | (1,266,944) | |||||
| Product [Member] | |||||||||
| Biosecurity revenue: | |||||||||
| Total Revenue | 10,788 | 3,887 | 22,454 | 17,834 | |||||
| Costs and operating expenses: | |||||||||
| Cost of Biosecurity revenue | 2,034 | 2,444 | 6,575 | 10,539 | |||||
| Service [Member] | |||||||||
| Biosecurity revenue: | |||||||||
| Total Revenue | 24,497 | 96,489 | 59,437 | 229,459 | |||||
| Costs and operating expenses: | |||||||||
| Cost of Biosecurity revenue | 16,062 | 61,467 | 33,896 | 138,804 | |||||
| Cell Engineering revenue [Member] | |||||||||
| Biosecurity revenue: | |||||||||
| Total Revenue | [2] | $ 45,283 | $ 44,242 | $ 79,379 | $ 65,730 | ||||
| |||||||||
DNA Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 1,105,787 | $ 1,315,792 |
| Accounts receivable, net | 68,019 | 80,907 |
| Accounts receivable - related parties | 899 | 1,558 |
| Inventory, net | 391 | 4,364 |
| Prepaid expenses and other current assets | 48,357 | 47,458 |
| Total current assets | 1,223,453 | 1,450,079 |
| Property, plant, and equipment, net | 294,244 | 314,773 |
| Operating lease right-of-use assets | 391,430 | 400,762 |
| Investments | 119,944 | 112,188 |
| Equity method investments | 1,120 | 1,543 |
| Intangible assets, net | 105,033 | 111,041 |
| Goodwill | 58,829 | 60,210 |
| Other non-current assets | 97,946 | 88,725 |
| Total Assets | 2,291,999 | 2,539,321 |
| Current liabilities: | ||
| Accounts payable | 13,630 | 10,451 |
| Deferred revenue (includes $6,473 and $10,309 from related parties) | 39,223 | 47,817 |
| Accrued expenses and other current liabilities | 110,478 | 114,694 |
| Total current liabilities | 163,331 | 172,962 |
| Non-current liabilities: | ||
| Deferred revenue, net of current portion (includes $132,799 and $131,188 from related parties) | 179,903 | 174,767 |
| Operating lease liabilities, non-current | 410,938 | 413,256 |
| Warrant liabilities | 14,146 | 10,868 |
| Other non-current liabilities | 20,096 | 31,191 |
| Total Liabilities | 788,414 | 803,044 |
| Commitments and contingencies (Note 7) | ||
| Shareholders' equity: | ||
| Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued | 0 | 0 |
| Common stock, $0.0001 par value (Note 6) | 196 | 190 |
| Additional paid-in capital | 6,280,632 | 6,136,378 |
| Accumulated deficit | (4,775,943) | (4,397,659) |
| Accumulated other comprehensive loss | (1,300) | (2,632) |
| Total stockholders equity | 1,503,585 | 1,736,277 |
| Total Liabilities and Shareholders' Equity | $ 2,291,999 | $ 2,539,321 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.